Benchmarking of the quality of the transfusion policy in Belgian hospitals between 2012-2016 – a collaborative and iterative method

Abstract

Background  Direct oral anticoagulants (DOACs) prolong PT/aPTT and affect other coagulations tests, including lupus anticoagulant (LA) screening 1 .  DOAC-Stop® (Haematex) promises to remove DOACs from patient plasma with minimal effect on blood clotting tests.  Objective 1. Determining the impact of DOACs on LA screening. 2. Evaluation of DOAC-Stop® for LA screening in patients receiving DOAC therapy.